This approach is a more likely strategy for dealing with all FVIII mutant variants because the FVIII transgene can express the functional FVIII protein, regardless of mutant variants of hemophilia A. In this way, a single set of genes targeting an engineered nuclease and the FVIII gene donor plasmid is sufficient to address virtually all hemophilia A mutant types. Here, F8 is linked to hemophilia A.